Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Phase II Trial to Evaluate Anti-tumor Activity and Safety of CLDN6 CAR-T ± CLDN6 RNA-LPX in Male Participants With Relapsed or Refractory Claudin 6-positive Testicular or Extragonadal Germ Cell Tumors

Next Previous
Trial Profile

Open-label Phase II Trial to Evaluate Anti-tumor Activity and Safety of CLDN6 CAR-T ± CLDN6 RNA-LPX in Male Participants With Relapsed or Refractory Claudin 6-positive Testicular or Extragonadal Germ Cell Tumors

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNT 211 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Germ cell cancer; Testicular cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AVENTURINE
  • Sponsors BioNTech

Most Recent Events

  • 23 Apr 2025 Status changed from planning to not yet recruiting.
  • 05 Aug 2024 According to a BioNTech media release, based on real-world evidence data presented at the 2024 ASCO Annual Meeting, company will inform the design of the Company's planned pivotal clinical trial to evaluate BNT211 in patients with germ cell tumors.
  • 05 Aug 2024 According to a BioNTech media release, pivotal Phase 2 trial in patients with testicular germ cell tumors is expected to start in 2025 based on encouraging data in this patient group observed in the Phase 1 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top